LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/04/2026
Back to search
Official data from USPTO
LENTINEXT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
06/05/2026
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
06/22/2023
Registration date
09/24/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/24/2024
Last transaction
06/05/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
LAVACHE, LINDA M
Law office
L60
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
BioDesign Lab Co., Ltd.
Representatives
Jong Park The PL Law Group, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Gene transfer agents for preventing and treating human vector-borne diseases; biological preparations, namely, biological vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations, namely, biological recombinant vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations for gene recombination for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); nucleic acids for medical, medicinal or veterinary purposes; biopharmaceuticals for the treatment of auto-immune diseases; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; reagents for use in medical genetic testing; pharmaceutical preparations for gene therapy and diagnosis of auto-immune diseases and cancer; pharmaceutical preparations for the diagnosis and the treatment of auto-immune diseases; anti-cancer preparations; antibiotics; anti-viral agents; anti-infectives; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer cells; cells for medical purposes
Publications
History of USPTO decisions and trademark events.
30 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/22/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/02/2025
FIMP
FINAL DISPOSITION PROCESSED
03/02/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/25/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/08/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/08/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/24/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/24/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
09/24/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/09/2024
PUBO
PUBLISHED FOR OPPOSITION
07/09/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/19/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/30/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
05/30/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/30/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
05/30/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/30/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/09/2024
RFNT
REFUSAL PROCESSED BY IB
04/23/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/03/2024
RFRR
REFUSAL PROCESSED BY MPU
04/03/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/16/2024
CNRT
NON-FINAL ACTION WRITTEN
03/15/2024
DOCK
ASSIGNED TO EXAMINER
03/11/2024
MAFR
APPLICATION FILING RECEIPT MAILED
08/15/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/11/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/10/2023
Continuous trademark protection
Get notified about every new filing that threatens LENTINEXT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.